FDA recommends collecting ovarian toxicity data in cancer drug trials

Regulatory NewsRegulatory NewsBiologics/ biosimilars/ vaccinesGuidancePharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)